Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 4
2021 10
2022 8
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Cutaneous Lupus Erythematosus: Progress and Challenges.
Petty AJ, Floyd L, Henderson C, Nicholas MW. Petty AJ, et al. Among authors: floyd l. Curr Allergy Asthma Rep. 2020 Apr 4;20(5):12. doi: 10.1007/s11882-020-00906-8. Curr Allergy Asthma Rep. 2020. PMID: 32248318 Free PMC article. Review.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Is open access a misnomer?
Floyd L, Stauss M, Woywodt A. Floyd L, et al. Lancet. 2022 Mar 26;399(10331):1226. doi: 10.1016/S0140-6736(22)00107-6. Lancet. 2022. PMID: 35339224 No abstract available.
The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials.
Bate S, McGovern D, Costigliolo F, Tan PG, Kratky V, Scott J, Chapman GB, Brown N, Floyd L, Brilland B, Martín-Nares E, Aydın MF, Ilyas D, Butt A, Nic An Riogh E, Kollar M, Lees JS, Yildiz A, Hinojosa-Azaola A, Dhaygude A, Roberts SA, Rosenberg A, Wiech T, Pusey CD, Jones RB, Jayne DRW, Bajema I, Jennette JC, Stevens KI, Augusto JF, Mejía-Vilet JM, Dhaun N, McAdoo SP, Tesar V, Little MA, Geetha D, Brix SR. Bate S, et al. Among authors: floyd l. J Am Soc Nephrol. 2024 Mar 1;35(3):335-346. doi: 10.1681/ASN.0000000000000274. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082490
Risk Stratification to Predict Renal Survival in Anti-Glomerular Basement Membrane Disease.
Floyd L, Bate S, Hadi Kafagi A, Brown N, Scott J, Srikantharajah M, Myslivecek M, Reid G, Aqeel F, Frausova D, Kollar M, Kieu PL, Khurshid B, Pusey CD, Dhaygude A, Tesar V, McAdoo S, Little MA, Geetha D, Brix SR. Floyd L, et al. J Am Soc Nephrol. 2023 Mar 1;34(3):505-514. doi: 10.1681/ASN.2022050581. Epub 2022 Nov 29. J Am Soc Nephrol. 2023. PMID: 36446430 Free PMC article.
Teledermatology: How It Is Impacting the Underserved.
Hadeler E, Prose N, Floyd LP. Hadeler E, et al. Among authors: floyd lp. Pediatr Dermatol. 2021 Nov;38(6):1597-1600. doi: 10.1111/pde.14838. Epub 2021 Oct 14. Pediatr Dermatol. 2021. PMID: 34648665
30 results